Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

292 views

Visitors from

US 53%·

AU 34%·

IN 7%·

GB 2%·

HK 1%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Stryker Launches New Tendon Fixation Device System

By: Stryker via Business Wire

September 15, 2021 at 08:05 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Citrelock™ Differentiated Design Features Citregen™, A Bioresorbable Material

Stryker’s Trauma & Extremities division has launched its Citrelock™ Tendon Fixation Device System. The new system provides surgeons a differentiated design via a tendon thread featuring a resorbable technology, known as Citregen™, that has unique chemical and mechanical properties for orthopaedic surgical applications. Stryker will debut Citrelock at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting, Sept. 22-25, 2021, in Charlotte, N.C.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005253/en/

Stryker's new Citrelock™ Tendon Fixation Device System provides surgeons a differentiated design via a tendon thread featuring a resorbable technology, known as Citregen™, that has unique chemical and mechanical properties for orthopaedic surgical applications. (Photo: Business Wire)

“Our customers are looking for a more predictable and effective bioresorbable material than what is currently on the market,” said Michael Rankin, VP Marketing and Medical Education, Stryker Foot & Ankle. “The Citrelock Tendon Fixation Device System helps fill that need with its innovative material technology and unique design. Citregen is an exciting addition to Stryker’s existing biomaterial portfolio and will be expanded for use in additional Stryker Trauma & Extremities indications in the future.”

The Citrelock Tendon Fixation Device System offers surgeons:

A controlled and homogeneous resorption process that prevents bulk degradation and chronic inflammation.¹
Compressive strength that is comparable to cortical bone with a modulus comparable to cancellous bone.^1,2
Citregen contains citrate, calcium, and phosphate molecules that are inherent to the bone anatomy.¹
Material polymer structure that mimics the extracellular matrix protein network.¹
Citregen maintains structural integrity during the healing phase, while the implant is replaced by host tissue over time.¹

“By leveraging Citregen’s unique material properties, the Citrelock Tendon Fixation Device System introduces design features to ease insertion and secure fixation without damaging the tendon during placement,” said Wayne Berberian, MD, orthopaedic surgeon at HMH Hackensack University Medical Center. “It has been exciting to observe the development of a biomaterial for use in orthopaedic applications. I’m excited to start using Citrelock in my practice.”

Citrelock will be featured during one of Stryker’s industry sessions at AOFAS on September 24. The company is also hosting a new product reception highlighting the benefits of Citrelock along with other recent additions to its Foot & Ankle portfolio. For more information, visit www.stryker-trauma.live/aofas-2021/ or stop by the Stryker booth (No. 425).

About Stryker

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at www.stryker.com.

Follow Stryker Foot & Ankle on LinkedIn and Stryker’s Trauma & Extremities division on Twitter.

FDA 510(k) K200725
TM-190301

A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery.

The information presented is intended to demonstrate the breadth of Stryker’s product offerings. A surgeon must always refer to the package insert, product label and/or instructions for use before using any of Stryker’s products. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your sales representative if you have questions about the availability of products in your area.

CITE-BL-1, 08-2021

View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005253/en/

Contacts

Andrea Sampson, Sampson Public Relations Group

asampson@sampsonprgroup.com

562.304.0301

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	268.26	+3.20 (1.21%)
AAPL	280.14	+8.79 (3.24%)
AMD	360.54	+6.05 (1.71%)
BAC	53.24	-0.22 (-0.41%)
GOOG	383.22	+1.28 (0.34%)
META	608.75	-3.16 (-0.52%)
MSFT	414.44	+6.66 (1.63%)
NVDA	198.45	-1.12 (-0.56%)
ORCL	171.83	+10.44 (6.47%)
TSLA	390.82	+9.19 (2.41%)